ArticleMedicine2026
Association of CYP2C19 genetic polymorphisms with dyslipidemia and ischemic cerebrovascular disease in the mongolian population: A case-control study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the role of cytochrome P450 2C19 (CYP2C19) gene polymorphisms and dyslipidaemic metabolism in ischemic cerebrovascular disease among Mongolian patients, analyzing their interaction with conventional risk factors. This case-control study enrolled 300 patients with ischemic cerebrovascular disease: 150 Mongolian patients (observation group) receiving CYP2C19 genotype-guided treatment and 150 Han Chinese patients (control group) undergoing standard care. Baseline characteristics, lipid profiles, CYP2C19 genotypes, NIHSS, and activities of daily living scores were analyzed. Baseline characteristics and CYP2C19 genotype distributions showed no significant differences between groups (P > .05). Multivariate logistic regression revealed that the poor metaboliser phenotype significantly increased the risk of ischemic cerebrovascular disease odds ratio (OR) = 2.31, 95% confidence interval: 1.25-4.26, P = .008), alongside hypertension (OR = 1.87, P = .043) and diabetes mellitus (OR = 2.12, P = .024). Dyslipidaemia prevalence was marginally but not significantly higher across genotypes in the Mongolian group. After 3 months of treatment, the genotype-guided observation group exhibited significantly greater reductions in total cholesterol and low-density lipoprotein cholesterol, and a slight increase in high-density lipoprotein cholesterol (P < .05). Furthermore, the observation group demonstrated significantly superior neurological recovery National Institutes of Health Stroke Scale and improved daily functioning (ADL) compared to the control group (P < .001). CYP2C19 poor-metaboliser status is associated with an increased risk of ischemic cerebrovascular disease in the Mongolian population and may contribute to dyslipidaemia and treatment response heterogeneity. Individualised intervention guided by CYP2C19 genotyping offers potential benefits in improving lipid profiles, neurological function, and short-term outcomes, serving as a valuable tool for precision medicine in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.